A Randomised, Open, Placebo-controlled 5-way Crossover Trial of Single Doses of Intranasal GSK256066 in Subjects With Seasonal Allergic Rhinitis (SAR).

This current study is planned as a dedicated pharmacodynamic (effect of drug on the body) study to investigate the dose response in rhinitic subjects at doses where GSK256066 has been proven to work (200mcg) or expected to (50mcg) work. This study also aims to investigate the lower end of the predicted therapeutic range.

本研究为一项专门的药效动力学（pharmacodynamic，即药物对机体的作用）研究，旨在探究鼻炎受试者在GSK256066已被证实有效的剂量（200mcg）及预期有效的剂量（50mcg）下的量效关系。本研究同时旨在考察该药物预测治疗范围的下限。